Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DocMorris AG (DOCM.SW)
CHF10.24
+0.08 (+0.79%)
CH SIX Healthcare Medical - Distribution
Address
Walzmühlestrasse 49 8500
Frauenfeld, CH
Frauenfeld, CH
CEO
Walter Hess
Website
corporate.docmorris.com/en
IPO
2017-07-06
ISIN CH0042615283
Also trades on
London Stock Exchange · 0RRB.L (CHF)
Other OTC · ZRSEF (USD)
Swiss Exchange · DOCM.SW (CHF)
Swiss Exchange · ROSE.SW (CHF)
Description
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF10.24
+0.08 (+0.79%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
344.3K
Beta
1.86
Float Shares
34.97M
Free Float %
71.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.37% | +5.00% | -1.05% | +36.07% | +27.91% | +17.45% | -16.84% | -76.80% | -97.91% | -95.35% | -95.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
10.24
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 5 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.30
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%+10.6% ★ Q4'25: +15.1% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%+36.0% ★ Q4'25: +80.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-8.5% Q4'25: +9.7% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%-7.5% Q4'25: -5.3% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%-15.4% Q4'25: -22.4% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+115.5% Q4'25: +116.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-7.33× Q4'25: -8.28× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
982.92M
est: 982.91M (+0.0%)
|
1.21B
est: 1.21B (+0.1%)
|
1.36B
est: 1.42B (-4.5%)
|
1.48B
est: 1.61B (-8.5%)
|
1.73B
est: 1.75B (-1.4%)
|
930.97M
est: 1.61B (-42.1%)
|
969.46M
est: 1.00B (-3.3%)
|
1.02B
est: 1.02B (-0.4%)
|
1.12B
est: 1.12B (+0.3%)
|
1.21B
1.20B – 1.24B
+8.3% YoY
|
1.33B
1.25B – 1.52B
+9.3% YoY
|
1.45B
1.44B – 1.46B
+9.0% YoY
|
1.67B
1.60B – 1.81B
+15.1% YoY
|
1.86B
1.79B – 2.02B
+11.5% YoY
|
| EBITDA |
-22.42M
est: -68.71M (+67.4%)
|
-17.99M
est: -84.26M (+78.7%)
|
-13.67M
est: -99.21M (+86.2%)
|
-76.13M
est: -112.89M (+32.6%)
|
-150.84M
est: -122.45M (-23.2%)
|
-109.79M
est: -112.46M (+2.4%)
|
-54.57M
est: -66.79M (+18.3%)
|
-37.02M
est: -68.02M (+45.6%)
|
-39.40M
est: -74.67M (+47.2%)
|
-80.86M
-82.69M – -79.63M
-8.3% YoY
|
-88.40M
-101.21M – -83.16M
-9.3% YoY
|
-96.38M
-96.92M – -95.85M
-9.0% YoY
|
-110.98M
-120.68M – -106.70M
-15.1% YoY
|
-123.73M
-134.54M – -118.96M
-11.5% YoY
|
| EBIT |
-34.21M
est: -105.44M (+67.6%)
|
-36.85M
est: -129.30M (+71.5%)
|
-44.24M
est: -152.24M (+70.9%)
|
-114.17M
est: -173.23M (+34.1%)
|
-200.70M
est: -187.90M (-6.8%)
|
-149.43M
est: -172.58M (+13.4%)
|
-98.00M
est: -107.10M (+8.5%)
|
-82.60M
est: -109.07M (+24.3%)
|
-84.29M
est: -119.74M (+29.6%)
|
-129.66M
-132.60M – -127.69M
-8.3% YoY
|
-141.76M
-162.31M – -133.35M
-9.3% YoY
|
-154.56M
-155.42M – -153.70M
-9.0% YoY
|
-177.97M
-193.52M – -171.10M
-15.1% YoY
|
-198.41M
-215.75M – -190.76M
-11.5% YoY
|
| Net Income |
-36.24M
est: -26.97M (-34.4%)
|
-38.97M
est: -22.62M (-72.3%)
|
-52.36M
est: -28.39M (-84.4%)
|
-135.70M
est: -48.18M (-181.6%)
|
-225.74M
est: -108.57M (-107.9%)
|
-171.12M
est: -81.21M (-110.7%)
|
82.28M
est: -441.87M (+118.6%)
|
-97.25M
est: -204.50M (+52.4%)
|
-134.40M
est: -134.40M (0.0%)
|
-84.15M
-135.22M – -73.15M
+37.4% YoY
|
-48.29M
-101.72M – -41.64M
+42.6% YoY
|
-23.38M
-49.60M – -6.13M
+51.6% YoY
|
-2.34M
-2.60M – -2.22M
+90.0% YoY
|
23.20M
22.04M – 25.83M
+1,092.8% YoY
|
| SGA |
87.65M
est: 137.46M (-36.2%)
|
99.31M
est: 168.57M (-41.1%)
|
88.10M
est: 198.48M (-55.6%)
|
160.62M
est: 225.83M (-28.9%)
|
226.28M
est: 244.96M (-7.6%)
|
165.39M
est: 224.99M (-26.5%)
|
122.10M
est: 118.42M (+3.1%)
|
158.48M
est: 120.60M (+31.4%)
|
—
est: 132.40M (-100.0%)
|
143.37M
141.19M – 146.62M
+8.3% YoY
|
156.75M
147.45M – 179.47M
+9.3% YoY
|
170.90M
169.95M – 171.86M
+9.0% YoY
|
196.79M
189.20M – 213.98M
+15.1% YoY
|
219.39M
210.93M – 238.56M
+11.5% YoY
|
| EPS |
-3.24
est: -2.29 (-41.7%)
|
-3.02
est: -1.92 (-57.5%)
|
-2.98
est: -2.41 (-23.8%)
|
-7.36
est: -4.09 (-80.1%)
|
-11.52
est: -9.21 (-25.1%)
|
-7.78
est: -6.74 (-15.5%)
|
-4.79
est: -8.30 (+42.3%)
|
-4.06
est: -3.84 (-5.7%)
|
-2.60
est: -2.40 (-8.5%)
|
-1.79
-2.62 – -1.42
+25.3% YoY
|
-1.13
-1.97 – -0.81
+36.8% YoY
|
-0.59
-0.96 – -0.12
+48.0% YoY
|
-0.05
-0.05 – -0.04
+92.3% YoY
|
0.45
0.43 – 0.50
+1,092.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-53.65M
OE per share TTM
-3.23
Owner's Yield
-14.76%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 8 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amplify Online Retail ETF IBUY | 0.77% | 840.7K | 0.65% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.06% | 513.6K | 0.40% |
| 3 | iShares Digitalisation UCITS ETF DGTL.L | 0.02% | 133.2K | 0.40% |
| 4 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.02% | 1.08M | 0.10% |
| 5 | Dimensional - International Vector Equity ETF DXIV | 0.01% | 13.8K | 0.53% |
| 6 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 365.5K | 0.28% |
| 7 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 16.8K | 0.07% |
| 8 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 404.2K | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-58.0K
Shares Outstanding
48.64M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Walter Hess | Chief Executive Officer & Member of Executive Board | 1M | male |
| Pablo Ros | Chief Technology Officer & Member of Executive Board | 1M | male |
| Walter Oberhansli | Founder & Chairman | 384.0K | male |
| David Maso | Chief AI Health Officer & Member of Executive Board | — | male |
| Andrea Skersies | Chief Commercial Officer & Member of the Executive Board | — | female |
| Torben Bonnke | Director of Communications | — | — |
| Kaspar Niklaus | Chief Operating Officer & Member of Executive Board | — | male |
| Daniel Grigat | Group Head of Investor Relations & Sustainability | — | — |
| Daniel Wüest | Chief Financial Officer & Member of Executive Board | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DOCM.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
